- Home
- SILC vs CGEN Comparison
SILC vs CGEN Comparison
Compare SILC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- CGEN
- Stock Information
- Founded
- SILC 1987
- CGEN 1993
- Country
- SILC Israel
- CGEN Israel
- Employees
- SILC N/A
- CGEN N/A
- Industry
- SILC Computer Manufacturing
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SILC Technology
- CGEN Health Care
- Exchange
- SILC Nasdaq
- CGEN Nasdaq
- Market Cap
- SILC 86.2M
- CGEN 167.4M
- IPO Year
- SILC 1994
- CGEN 2000
- Fundamental
- Price
- SILC $15.27
- CGEN $1.58
- Analyst Decision
- SILC Hold
- CGEN
- Analyst Count
- SILC 2
- CGEN 0
- Target Price
- SILC N/A
- CGEN N/A
- AVG Volume (30 Days)
- SILC 12.6K
- CGEN 154.0K
- Earning Date
- SILC 07-31-2025
- CGEN 08-05-2025
- Dividend Yield
- SILC N/A
- CGEN N/A
- EPS Growth
- SILC N/A
- CGEN N/A
- EPS
- SILC N/A
- CGEN N/A
- Revenue
- SILC $58,134,000.00
- CGEN $27,589,000.00
- Revenue This Year
- SILC $6.26
- CGEN N/A
- Revenue Next Year
- SILC $19.14
- CGEN $105.77
- P/E Ratio
- SILC N/A
- CGEN N/A
- Revenue Growth
- SILC N/A
- CGEN N/A
- 52 Week Low
- SILC $11.35
- CGEN $1.13
- 52 Week High
- SILC $18.24
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- SILC 50.22
- CGEN 43.53
- Support Level
- SILC $14.93
- CGEN $1.66
- Resistance Level
- SILC $15.93
- CGEN $1.74
- Average True Range (ATR)
- SILC 0.55
- CGEN 0.09
- MACD
- SILC -0.01
- CGEN -0.02
- Stochastic Oscillator
- SILC 31.78
- CGEN 14.41
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.